USD 1.61
(2.55%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -6.23 USD | -102.27% |
2022 | -3.08 USD | -62.96% |
2021 | -1.89 USD | -182.09% |
2020 | -0.67 USD | -1443.78% |
2019 | -0.07 USD | 72.88% |
2018 | -0.16 USD | 0.0% |
2017 | -0.16 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.44 USD | -340.0% |
2024 Q1 | -0.10 USD | 95.71% |
2023 Q2 | -1.07 USD | 70.19% |
2023 Q3 | -1.63 USD | -52.34% |
2023 FY | - USD | -102.27% |
2023 Q1 | -3.59 USD | -870.27% |
2023 Q4 | -2.33 USD | -42.94% |
2022 Q3 | -0.92 USD | 13.21% |
2022 Q2 | -1.06 USD | -47.22% |
2022 Q1 | -0.72 USD | 1.37% |
2022 FY | - USD | -62.96% |
2022 Q4 | -0.37 USD | 59.78% |
2021 FY | - USD | -182.09% |
2021 Q4 | -0.73 USD | -108.57% |
2021 Q3 | -0.35 USD | -2.94% |
2021 Q2 | -0.34 USD | 26.09% |
2021 Q1 | -0.46 USD | -84.0% |
2020 Q4 | -0.25 USD | -66.67% |
2020 Q3 | -0.15 USD | 55.88% |
2020 Q2 | -0.34 USD | -254.17% |
2020 FY | - USD | -1443.78% |
2020 Q1 | -0.10 USD | -119.18% |
2019 Q1 | -0.04 USD | -13.61% |
2019 Q4 | -0.04 USD | 24.22% |
2019 Q3 | -0.06 USD | 26.18% |
2019 FY | - USD | 72.88% |
2019 Q2 | -0.08 USD | -80.41% |
2018 Q4 | -0.04 USD | -22.04% |
2018 FY | - USD | 0.0% |
2018 Q3 | -0.03 USD | 36.9% |
2018 Q2 | -0.05 USD | -14.81% |
2018 Q1 | -0.04 USD | 0.0% |
2017 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ADC Therapeutics SA | -2.94 USD | -111.905% |
Alto Neuroscience, Inc. | -1.35 USD | -361.481% |
Biohaven Pharmaceutical Holding Company Ltd. | -5.73 USD | -8.726% |
Ginkgo Bioworks Holdings, Inc. | -18.37 USD | 66.086% |
Nuvation Bio Inc. | -0.35 USD | -1680.0% |
Nuvation Bio Inc. | -0.35 USD | -1680.0% |
Arcus Biosciences, Inc. | -4.15 USD | -50.12% |
Zymeworks Inc. | -1.72 USD | -262.209% |